Investor Presentaiton

12 First-Line MUM Clinical Efficacy Observed Compelling Confirmed Overall Response Rate and Disease Control Rate Darovasertib + Crizotinib Phase 2 First-Line MUM (n= 20) Confirmed 45% ORR and 90% DCR Best Tumor Response (%) 60% 50% 40% 30% 20% 10% 0% -10% -20% -30% ess -40% -50% -60% -70% -80% + Confirmed Partial Response + + Response by RECIST 1.1 Evaluable First-Line MUM (N=20) Confirmed ORR (9/20) 45% PD Tumor Shrinkage (19/20) 95% >30% Tumor Shrinkage (11/20) 55% SD Best Overall Response CPR (9/20) 45% PR uPR (1/20) 5% SD (8/20) 40% DCR (18/20) 90% Clinical Efficacy supports Registrational Strategy in First-Line MUM to Enhance Patient Benefit IDEAYA Data: preliminary analysis of unlocked database as of 03/08/2023 by investigator review; data cutoff based on treatment Day 1 of Cycle 1 (C1D1) as of 9/22/2022, based on 20 evaluable First-Line MUM patients ORR = Overall Response Rate; DCR = Disease Control Rate; CPR = Confirmed Partial Response; uPR = Unconfirmed Partial Response; SD = Stable Disease IDEAVA BIOSCIENCES

View entire presentation